Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has issued an announcement.
MindBio Therapeutics Corp. has enrolled its 80th participant in a landmark Phase 2B clinical trial for MB22001, a proprietary formulation for Major Depressive Disorder (MDD). This trial, nearing completion, highlights MindBio’s commitment to developing scalable, patient-centric mental health treatments. The company is the only one globally to have regulatory approval for at-home microdosing of psychedelic medicines, demonstrating significant improvements in mood and depressive symptoms. MindBio is also conducting trials for cancer-related existential distress and pre-menstrual disorders, further showcasing the versatility of its therapeutic platform.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing novel psychedelic-based medicines for mental health disorders. The company is dedicated to creating innovative, accessible, and affordable treatments to address the global mental health crisis.
Average Trading Volume: 141,984
Technical Sentiment Signal: Sell
Learn more about MBIO stock on TipRanks’ Stock Analysis page.